Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 0.875p 500,976 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.75p 1.00p 0.875p 0.875p 0.875p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.47 -0.30 -0.11 3.3

Feedback (FDBK) Latest News

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-06-19 14:26:000.90109,890989.01O
2019-06-19 12:08:290.7665,000495.63O
2019-06-19 11:06:380.92326,0862,999.99O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
19/6/2019
09:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 0.88p.
Feedback Plc has a 4 week average price of 0.58p and a 12 week average price of 0.58p.
The 1 year high share price is 2.78p while the 1 year low share price is currently 0.58p.
There are currently 373,283,250 shares in issue and the average daily traded volume is 260,628 shares. The market capitalisation of Feedback Plc is £3,266,228.44.
06/6/2019
09:37
kinwah: Times article today on the NHS looking to fast-track new machine learning technologies. At least it has given the FDBK share price a boost.
29/5/2019
18:51
hedgehog 100: From the IQAI thread: LR2 8 May '19 - 20:59 - 136 of 193 " ... Regarding Trevor Brown, I'd never bumped into him before Feedback but when I did I was disgusted at aspects of his behaviour and decided to investigate him. That was enlightening. The main thing I found at that time was him posting both here and elsewhere under two different pseudonyms and what he posted was, I believed, detrimental to Feedback in general and TexRAD in particular. Ironic really when TexRAD was, and still is, the core software component of Stone Checker. ... " LR2, As promised after your postings on the IQAI thread today, I am paying a 'return visit' ... it would be rude not to! Are you aware of the irony of your being 'so disgusted' at someone posing negative comments about a company? So disgusted apparently that you decide to do exactly the same yourself! And under two different pseudonyms (LR2 here, and Elartu on LSE). And your grudge against Trevor Brown seems to be a classic case of 'shooting the messenger for the message'. You don't like the fact that he flagged up some time ago that FDBK had the wrong strategy. Though all the evidence suggests that he was absolutely right. So if you're going to get angry against anyone, surely you should get angry with the FDBK directors who ignored his advice, rather than with TB for giving that advice? Or am I missing something? It's also deeply concerning that you apparently wish that this important information for investors in FDBK should have been suppressed. So let me set out a few home truths about FDBK. Let's make it a round ten, shall we? (Albeit they're probably obvious to many FDBK shareholders here ... how many have I heard say 'it's just not worth me selling now ...'?) - • Public question marks about the company's strategy. • A pitiful 4% sales growth (at its interim stage) after years of trying. • £738K. annualised pre-tax losses at the interim stage. • Those losses will increase with the recruitment drive etc. • Current cash likely to be below £1M., probably enough for about a year. • Little potential short term excitement expected. • No exciting growth story. • Chart in an entrenched downtrend, and generally declining trading volumes. • No recent director share buying, despite the depressed share price, and not being in a close period. • By the end of 2019 FDBK will be in fundraising countdown mode, with one due within months by then. Who would like to predict the price of FDBK's next fundraising? Current share price 0.725p, market cap. £2.71M. Don't be surprised if IQAI's sales in the current year are actually HIGHER than FDBK's. As well as its losses and current market cap. (£1.44M. at 1.2p) being LOWER. And as regards turnover growth rate ... IQAI will just blow FDBK away.
24/5/2019
15:24
regina61: Interesting history lesson for investors here. Four years ago in June 11m shares were placed at 1.8p, raising £200k. The market cap was thus £3.6m (202m shares at 1.8p) post this 2015 placing. There are now 369m shares in issue but with the share price at 0.75p the market cap is £2.6m, i.e. £1m less. Have the overpaid Feedback directors invented a money shredding machine - the real meaning of texture analysis? Patents pending?
12/5/2019
15:10
hedgehog 100: From Feedback's interim results for the period ending 30.11.18: 4% growth in recognised revenue, and increasing losses (£738K. annualised pre-tax losses). And those losses will increase with the recruitment drive etc. 24/01/2019 07:00 UK Regulatory (RNS & others) Feedback PLC Half-year Results " ...Recognised revenue for the six-month period up 4% to GBP236k (H1 2018: GBP228k) -- Loss after tax for the six-month period of GBP369k (H1 2018: loss GBP348k) due to higher cost base … Feedback Medical is undertaking a recruitment drive to increase its in-house R&D and product management capability. It expects to appoint a research manager to assist with the expansion of Cadran and TexRAD(R) products into academic and commercial R&D support, as well as a small data science team to assist with data analysis and new algorithm development. ..." https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Half-year-Results/79108476 25/04/2019 07:00 UK Regulatory (RNS & others) Feedback PLC Trading update "Cambridge, 25 April 2019: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces a trading update for the financial year ending 31 May 2019. Following new hires and investment in product sales in the first half of the financial year, it is anticipated that Feedback will report significant growth in recognised revenue for the year ending 31 May 2019. The investment in new hires for Cadran, along with the agreement with Future Processing, signed in January 2019, to accelerate Feedback Medical's technology development and innovation, has increased the Company's cost base, the principal benefit of which will not be realised until the next financial year. As a result, the loss for the current financial year will reflect such investment but not the total anticipated income. ..." https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Trading-update/79761199 Cash at 30 November 2018 was GBP1.367M., so will now likely be below £1M. How long that lasts will depend upon how much losses increase by, but it could be about another year. So there's no urgent need to fundraise this year ... but therefore no urgent need to provide a stream of positive newsflow this year. In fact, the main potential short term excitement here seems to be that the new CEO will unveil a strategy for the company. Following on from the new strategy for the company unveiled by the previous CEO last June, shortly after which he promptly resigned: 07/06/2018 13:07 Alliance News Feedback Shares Drop After It Reveals New Growth Strategy LSE:FDBK Feedback 20/07/2018 09:20 Alliance News Feedback Shares Slip As Chief Executive David Crabb Departs LSE:FDBK Feedback
09/5/2019
10:26
ged5: Your figures for the accounts for 2017 and 2018 are correct. However the assets and liabilities could have several interpretations. I'll ask one of my daughters who is an accountant if she can shed any light on this. I see that in May 2016 FDBK agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal"). Then in June 2017 8,000,000 ordinary shares of £0.01 each in the capital of the Company (the Consideration Shares) to the shareholders of Stone Checker Software Limited (the Target) in connection with the acquisition by the Company of the Target (the Acquisition). I've seen elsewhere the share price was 3p. I'm not sure who held the other 50% at this time. I must admit I'm not really interested in IQAI other than: 1. How much royalties FDBK receives on any sales of Stonechecker 2. What are the circumstances where TexRAD may terminate this agreement 3. Can Stonechecker receive FDA approval before Texrad 4. If Stonechecker receives FDA approval will it improve Texrad's chance of approval? Answer to No. 2:- TexRAD Limited is entitled to terminate the Patents Licence if: (1) it is determined by an expert that the Target has without legitimate reason failed to use diligent and reasonable efforts to develop and commercially exploit the TexRAD Plug-in; (2) the Target is in material breach of the Patents Licence and such breach is not remedied, if capable of remedy, within 30 days; or (3) if the Target becomes insolvent. The Patents Licence requires the Target to pay TexRAD Limited royalty payments. Accordingly, if the Target failed to meet these payments and failed to remedy this breach within 30 days, and this was determined to be a material breach of the Patents Licence, TexRAD would be entitled to terminate the Patents Licence. Accordingly, a key risk is that the Patents Licence is terminated. Http://www.flyingbrands.co.uk/wp-content/uploads/2017/05/Notice_To_Investors_Checker_Prospectus_17_05_2017.pdf
03/5/2019
15:38
hedgehog 100: LR2, Obviously that was all he wanted to raise when the share price was depressed. That is very simple business and investment logic: you raise just the miniumum needed at a depressed share price, especially when there is a period of positive newsflow coming. So he did NOT pass round the hat, as involving just one other person cannot be described as passing something around. You are also being completely disingenuous re. the conversion price, and I believe that you know it. They could have set the conversion price at the current shareprice then of 1.275p, but they did not: they set it at a premium to that of over 50%. Well done I say on showing such respect to existing shareholders, and integrity. How many other companies are raising funds, via convertible loan notes or otherwise, at a premium of over 50%? You're also being ignorant of the FDA process: the 90 day turnaround is 90 days 'of the clock running': the clock can be stopped at any time while the FDA request more info. etc. FDA approvals generally seem to take longer than people expect so there's nothing unusual, and in this case the situation was aggravated by a one month US government shutdown. And I can't see why you think TexRAD needs to be approved separately and first. I would say if anything, it would make less sense for TexRAD itself to be approved first if it hasn't yet been approved for a specific application. I've read some of your obsessive, bitter comments about Trevor Brown, but from my research I have no concerns about him. For example, you suggested that he would take IQAI for an excessive salary. I checked, expecting something of £100K.+, but instead I found it to to £60K., which is perfectly reasonable. You appear to be embittered by the fact that he sold a lot of shares in Feedback, harming the value of your shareholding. But that was his right.
03/5/2019
14:13
hedgehog 100: LR21 May '19 - 17:28 - 710 of 720 " ... No wonder he had to cobble together a £268k issue of loan notes back in mid March. If he's paid his creditors by now he will be back to bare bones again cash wise. He might manage to crawl along for another month or so with the minimal cash coming in but I'm betting a pound to a penny that he will be passing the hat around again come July / August at the latest. ..." Ged5 30 Apr '19 - 14:09 - 701 of 720 "I see IQAI issued its annual report. Stonechecker mentioned. We still get some income from it. Says it's hoping for FDA approval later this year. It uses Texrad. It would seem a bit strange if Stonechecker got approval but Texrad hadn't already got it. LR2 knows more about this. Any thoughts?" LR2 and Ged5, You and LR2 are guilty of posting inaccuracies, which is rather ironic considering your attacks on Trevor Brown. Two from you I have quoted above. 1. Trevor Brown did not "pass round the hat" as you call it for the March 2019 fundraising: over 90% of it was subscribed for by himself, with the remainder subscribed for by the CEO of one of IQAI's subsidiaries: 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 2. IQAI did not say that "it's hoping for FDA approval later this year". Rather, it suggested that approval is expected far sooner that you are suggesting: 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report “ ... The Company is in the final stages of securing FDA approval for the StoneChecker software product and we hope to announce marketing clearance shortly, which would give the Company an additional and important revenue stream in the US during the 2nd half of 2019. ...” https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 LR2, If you are going to obsessively nit pick about Trevor Brown's terminology, then I would expect your own postings to be scrupulously accurate, but they are far from it. And as regards IQAI's March fundraising, you've completely ignored the two major positives re. that: 1. The fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p). 2. The investment of the two CEO's was akin to massive directors share buying, a huge vote of confidence in the company, especially at such a massive premium. In contrast, how many shares in Feedback has its new CEO bought? And what likelihood is there that Feedback could raise funds at a massive premium?
05/2/2019
19:37
tim000: Micro mkt cap shares are usually highly volatile due to the dominance of short-term (ie day) trading, since even fairly small trades can represent a relatively high proportion of the company's mkt cap (and hence will inevitably affect the share price). That in turn tends to drive others to trade in the same direction, resulting in upward/downward momentum. Witness the massive spikes and subsequent retraces for FDBK's share price. I'm sure you all know this. So a company that produces very little operational news is inevitably only going to appeal to longer term investors. Impatient investors are continually selling their stock, because of the opportunity costs of holding FDBK, ie not being able to trade micro cap stocks that are rising sharply. That doesn't mean there is a good reason to sell one's investment in FDBK. Personally I have no intention of selling, I have other funds that I can use to day trade - eg BMV and MATD at the moment!
13/12/2018
10:10
tim000: I think I know why the share price is weak! Reading the Holdings RNSs is a clue. I hold OPG. Look what happened there. The company suddenly had a good set of interims and the share price has gone up about 70%. It will probably continue to rise. I hope for a similar story here. But share price appreciation may only begin upon newsflow. And then I expect the appreciation to be sustained. I know seeing your shares go down is frustrating, but this really is a share where we have to be patient. Incidentally, the IQAI RNS today was interesting. Hopefully FDBK will learn lessons from their experience in getting FDA approval. IQAI are hoping for FDA approval within a year. If FDBK can achieve that, it will be a good result.
13/6/2018
11:49
lr2: Yes, but by indicating another money raising they've made it a lot harder for the share price in the short term. I don't blame the board as much as I do Trevor Brown. He decimated the share price by his pernicious selling over the previous 12 months. The board opted to raise a minimal amount at the very low price caused by Trevor Brown but they could have raised some more money (they still had the authority to do so) without calling for a special meeting. That is where, perhaps, they went wrong. Once the market was forewarned of a another likely raising lots of people sold up and pushed the share price downwards. And that is why the share price is where it is. When the clinical version of TexRAD sees light of day, that's when the share price lifts off.
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190620 00:07:37